Strontium ranelate is not metabolised and does not inhibit or induce CYP450 enzymes. Risk for gastrointestinal adverse events in the form of nausea and diarrhoea motivates vigilance against insufficient intake of food, especially of carbohydrate.

Strontium ranelate is indicated for the treatment of osteoporosis. Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are nausea, diarrhoea and loose stools.

Stronitum is a divalent cation and is not metabolised. It does not inhibit CYP450 enzymes (SPC).

Uneventful use reported in 2 patients with acute porphyria.